Оценка эффективности и безопасности омализумаба в комплексной терапии больных с тяжелой неконтролируемой атопической бронхиальной астмой в течение 12 месяцев наблюдения
https://doi.org/10.18093/0869-0189-2009-3-75-80
Аннотация
Об авторах
Ю.Б. СучковаРоссия
Г.Л. Осипова
Россия
А.Г. Чучалин
Россия
Т.Л. Пашкова
Россия
Список литературы
1. Beasley R., Crane J., Lai C.K., Pearce N. Prevalence and etiology of asthma. J. Allergy Clin. Immunok. 2000; 105: 466-472.
2. Global initiative for asthma (GINA); http: //www.ginasthma.com.
3. Принципы диагностики и лечения бронхиальной астмы в реальной клинической практике. Пульмонология и аллергология 2007; 3 (26): 3-10.
4. Фисенко В.П. Омализумаб (Ксолар): принципы действия, эффективность и безопасность. Пульмонология 2007; 5: 100-105.
5. Fick R.B. Jr. Anti-IgE as novel therapy for the treatment of asthma. Curr. Opin. Pulm. Med. 1999; 5: 76-80.
6. Noga O., Hanf G., Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. J. Int. Arch. Allergy Immunol. 2003; 131: 46-52.
7. MacGlashan D.W. Jr., Bochner B.S., Adelman D.C. et al. Down-regulation of human basophil IgE and FCepsilonRI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J. Immunol. 1999; 162: 5624-5630.
8. Hanf G., Brachmann I., Kleine-Tebbe J. et al. Omalizumab decreased IgE-release and induced changes in cellular imunity in patients with allergic asthma. Allergy 2006; 61: 1141-1144.
9. Noga O., Hanf G., Brachmann I. et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymfocyte function in patients with allergic asthma. J. Allergy Clin. Immunol. 2006; 1493-1499.
10. Busse W., Corren J., Lanier B.Q. et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 2001; 108 (2): 184-190.
11. Hendeles L., Sorkness C.A. Anti-immunoglobulin E therapy with omalizumab for asthma. Ann. Pharmacother. 2007; 41 (9):1397-1410.
12. Solèr M., Matz J., Townley R. et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. 2001; 18 (2): 254-261.
13. Cruz A.A., Lima F., Sarinho E. et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin. Exp. Allergy 2007; 37 (2): 197-207.
14. Limb S.L., Starke P.R., Lee C.E., Chowdhury B.A. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J. Allergy Clin. Immunol. 2007; 120 (6): 1378-1381.
15. Lanier B.Q., Corren J., Lumry W. et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann. Allergy Asthma Immunol. 2003; 91 (2): 154-915.
16. Corren J., Shapiro G., Reimann J. et al. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy. J. Allergy Clin. Immunol. 2008; 121 (2): 506-511.
17. Belliveau P.P., Lahoz M.R. Evaluation of omalizumab from a health plan perspective. J. Manag. Care Pharm. 2005; 11 (9): 735-745.
18. Juniper E.F., Guyatt G.H., Ferrie P.J. et al. Measuring quality of life in asthma. Am. Rev. Respir. Dis. 1993; 147: 832-838.
19. Thomas M., Kay S., Pike J. et al. The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Primary Care Respiratory J. 2009; 18 (1): 41-49.
Рецензия
Для цитирования:
Сучкова Ю., Осипова Г., Чучалин А., Пашкова Т. Оценка эффективности и безопасности омализумаба в комплексной терапии больных с тяжелой неконтролируемой атопической бронхиальной астмой в течение 12 месяцев наблюдения . Пульмонология. 2009;(3):75-80. https://doi.org/10.18093/0869-0189-2009-3-75-80